Paris, France — 15 December 2022 — Genèse Labs has expanded its distribution network to more than seven European countries between 2020 and 2022, building the commercial infrastructure that would underpin its later transition to in-house product development.

Although the European Union operates under a single cosmetics regulation, the aesthetics market in practice varies considerably from country to country in clinical convention, practitioner licensing and consumer expectation. A product that performs strongly in one market frequently requires entirely different positioning in another. Rather than pursuing uniform expansion, Genèse Labs adopted a country-by-country approach — selecting partners who already held established clinical networks and adapting training materials to each market’s treatment standards. This slowed early growth but produced far stronger results in partner retention.

The European market presents a structural reality: only lawfully notified products may be distributed within the EU. For many suppliers this becomes a persistent bottleneck, and reliance on external agencies costs both money and responsiveness. By building regulatory capability in-house, Genèse Labs was able to guarantee its partners complete documentation and a rapid response to the authorities — an administrative function that, in practice, became a service distributors valued in its own right.

By the end of 2022, the network had produced an asset more valuable than revenue: a continuous flow of information about which product categories were going unmet, which formulations practitioners were requesting but could not source, and where existing products fell short in handling and longevity. This accumulated knowledge became the direct basis for the company’s decision to become a brand owner and develop products under its own name.

Genèse Labs is a Paris-founded aesthetic company dedicated to science-based, regulatory-led product development across the fast-growing fields of body contouring, collagen biostimulation, and regenerative skincare. Since its foundation in 2019, the company has built its portfolio — including RG60®, Proluma™, Citrus Bottle™ and the Exoluma™ series — on three principles: scientifically verifiable formulations, regulatory compliance in every market entered, and continuous engagement with the international clinical and academic community. Genèse Labs partners with dermatologists, aesthetic physicians, and distributors worldwide to advance the standard of modern aesthetic medicine. For more information: www.geneselabs.net.